Form 4: LifeStance Health Group Chief Medical Officer Sells 16,000 Shares Under 10b5-1 Plan

LifeStance Health Group's Chief Medical Officer, Ujjwal Ramtekkar, reported the sale of 16,000 shares of common stock for approximately $5.94 per share, executed under a pre-arranged trading plan.

Summary

• Ujjwal Ramtekkar, the Chief Medical Officer of LifeStance Health Group, Inc. (LFST), reported the sale of 16,000 shares of the company's common stock.
• The transaction took place on June 5, 2025.
• The shares were sold at a weighted average price of $5.94, with individual sales ranging from $5.93 to $5.945 per share.
• Following this sale, Mr. Ramtekkar directly beneficially owns 113,435 shares of LifeStance Health Group common stock.
• The sale was conducted pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 4

Explanation: The sentiment is mildly negative due to the insider sale, as it represents a reduction in executive ownership. However, the negative impact is mitigated by the fact that the sale was executed under a pre-arranged Rule 10b5-1 plan, suggesting it was not based on new, adverse material information.

Positives

• The sale was executed under a Rule 10b5-1(c) plan, indicating it was a pre-scheduled transaction and not a reaction to immediate, non-public information, which can mitigate negative market interpretations.

Negatives

• An insider sale, particularly by a high-ranking officer like the Chief Medical Officer, can sometimes be perceived negatively by investors as it reduces the insider's direct stake in the company.

Risks

• While not explicitly stated as a risk in the document, insider selling, even under a 10b5-1 plan, can occasionally be interpreted by the market as a signal of an insider's belief that the stock's near-term upside may be limited.

Future Outlook

NA

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends for the healthcare or mental health services sector.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slightly negative signal, potentially influencing short-term sentiment or trading decisions, although the 10b5-1 plan context should be considered.

Key Dates

Recommendation

Keywords

LifeStance Health Group, LFST, Ujjwal Ramtekkar, Chief Medical Officer, Insider Sale, Form 4, SEC Filing, Stock Transaction, Rule 10b5-1, Healthcare Services